Abstract 1204TiP
Background
Patients (pts) with extensive-stage (ES) SCLC or extra-pulmonary grade 3 (G3) NEC rapidly develop progressive disease after 1st -line cytotoxic chemotherapy, and efficacious 2nd -line treatment options are needed. Lysine Specific Demethylase 1 (LSD1, aka KDM1A) is involved in repressing transcription by removing methyl groups from mono- and di-methylated lysine 4 of histone 3, epigenetic hallmarks commonly associated with actively transcribed genes. LSD1 over-expression is associated with tumor progression and worse prognosis, and its inhibition reduces cancer cell growth, migration, and invasion. The epigenetic drug iadademstat (aka ORY-1001 or iada) is a highly potent and selective LSD1 inhibitor (LSD1i) in phase 2 clinical development for malignant indications. Iada and other LSD1is are effective in in vitro and in vivo models of SCLC by preventing INSM1 recruitment of LSD1 which results in NOTCH signaling activation, reduced NE differentiation and tumor growth inhibition. Additionally, LSD1is have been implicated in reversing chemoresistance, synergizing with paclitaxel, and enhancing immunostimulatory responses by increasing MHC-Class I expression, IFN-Type I responses and T-cell infiltration and activity.
Trial design
NCT05420636 is a multi-center, non-randomized phase II study to treat up to 42 pts with iada (150 mg oral, 5d on-2d off every week) and paclitaxel (80 mg/m2 IV weekly) in 21 day cycles. Eligibility includes adult pts with metastatic/unresectable SCLC (cohort 1) or extra pulmonary G3 NEC or metastatic/unresectable prostate or bladder cancer with G3 NE or small cell component (cohort 2), who have received 1 to 3 prior lines of therapy and progressed on or after platinum-based chemotherapy. Pts must have measurable disease, normal organ, and marrow function, stable brain mets, ECOG status ≤1 and not have received prior taxanes for metastatic disease. The primary endpoint is ORR per RECIST 1.1; secondary endpoints include rate of ≥ grade 3 toxicities, PFS, OS and DoR. Exploratory endpoints include host inflammatory cytokine and immune profile, and epigenomic and genomic analysis of tumor and peripheral blood samples.
Clinical trial identification
NCT05420636.
Editorial acknowledgement
Legal entity responsible for the study
Fox Chase Cancer Center.
Funding
Oryzon.
Disclosure
N. Vijayvergia: Non-Financial Interests, Institutional, Local PI: BMS, ITM; Financial Interests, Personal, Advisory Board: Taiho, ITM; Non-Financial Interests, Institutional, Principal Investigator: Oryzon, Puma; Non-Financial Interests, Personal, Advisory Role: Rayze Bio. P. Ghatalia: Non-Financial Interests, Institutional, Research Funding: BMS, Oryzon, Merck. D. Faller: Financial Interests, Personal, Full or part-time Employment: Oryzon. A. Limon: Financial Interests, Personal, Full or part-time Employment: Oryzon. H.P. Soares: Financial Interests, Personal, Advisory Board: Tersera, Ipsen, AstraZeneca, Novartis, ITM. J. whetstine: Financial Interests, Institutional, Research Funding: Oryzon, Salarius Pharma; Financial Interests, Personal, Advisory Board: QSonica, Vyne Therapeutics, Daiichi Sankyo, Lily Asia Ventures. H. Borghaei: Financial Interests, Personal, Advisory Board: BMS, Genentech, Eli-Lilly, Merck, EMD-serono, AstraZeneca, Novartis, Genmab, Regeneron, Amgen, Takeda, PharmaMar, Jazz Pharma, Mirati, Daiichi, Guardant, Natera, Oncocyte, BeiGene, iTeo, Boehringer Ingelheim, Puma, BerGenbio, Janssen; Financial Interests, Personal, Other, Training discussion: Pfizer; Financial Interests, Personal, Other, DSMB: Novartis; Financial Interests, Institutional, Other, Clinical trial support: BMS, Amgen; Financial Interests, Personal, Stocks/Shares, Options for scientific advisory role: Sonnetbio; Financial Interests, Personal, Stocks/Shares, Options for scientific advisory board: Nucleai, Inspira (Rgenix); Financial Interests, Institutional, Trial Chair, Investigator initiated trial support: BMS; Financial Interests, Institutional, Coordinating PI, Investigator initiated trial support: Amgen, Lilly; Financial Interests, Personal and Institutional, Trial Chair, Chair steering committee: Miratti; Financial Interests, Personal and Institutional, Steering Committee Member: Amgen, AstraZeneca; Financial Interests, Personal, Steering Committee Member, Also trial support: BMS; Other, Other, DSMB: Novartis, Takeda, Incyte, Springworks. All other authors have declared no conflicts of interest.
Resources from the same session
1241P - Decoding the glycan code: Pioneering early detection of non-small cell lung cancer through glycoproteomics
Presenter: Kai He
Session: Poster session 14
1242P - Implementing functional precision oncology in real-world patients: Translating extensive in vitro data into personalized treatment combining genetics and functional assays
Presenter: Dörthe Schaffrin-Nabe
Session: Poster session 14
1243P - Ocular surface squamous neoplasia early diagnosis using an AI-empowered autofluorescence multispectral imaging technique
Presenter: Abbas HABIBALAHI
Session: Poster session 14
1244P - AI-based accurate PD-L1 IHC assessment in non-small cell lung cancer across multiple sites and scanners
Presenter: Ramona Erber
Session: Poster session 14
1245P - A lymph nodal staging assessment model for various histologic types of small intestinal tumors
Presenter: YOUSHENG LI
Session: Poster session 14
1246P - Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing
Presenter: Juan Blanco Heredia
Session: Poster session 14
1247P - A detection model for EGFR mutations in lung adenocarcinoma patients based on volatile organic compounds
Presenter: Yunpeng Yang
Session: Poster session 14
1248P - Development of a high performance and noninvasive diagnostic model using blood cell-free microRNAs for multi-cancer early detection
Presenter: Jason Zhang
Session: Poster session 14
1249P - Whole genome sequencing-based cancer diagnostics in routine clinical practice: An interim analysis of two years of real-world data
Presenter: Jeffrey van Putten
Session: Poster session 14
1250P - Assessing lung carcinoma: A retrospective study on volume evaluation, consolidation and infiltration using chest OMX
Presenter: Swarnambiga Ayyachamy
Session: Poster session 14